Article Text

PDF
Systematic review with meta-analysis
Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality
  1. Muhammad U Farooq,
  2. Philip B Gorelick
  1. Department of Vascular Neurology and Stroke, Hauenstein Neuroscience Center, Grand Rapids, Michigan, USA
  1. Correspondence to: Dr Muhammad U Farooq
    Department of Vascular Neurology and Stroke, Hauenstein Neuroscience Center, 220 Cherry St SE, Grand Rapids, MI 49503, USA; farooqmu{at}trinity-health.org

Statistics from Altmetric.com

Commentary on:

Context

Prophylactic antiplatelet therapy with aspirin reduces the risk of non-fatal myocardial infarction (MI), non-fatal stroke and vascular death in patients with known cardiovascular disease (CVD) and is of net benefit. The absolute reduction in recurrent events significantly exceeds the increase in major bleeding.1 However, the role of aspirin in primary prevention of CVD is not clear. According to the Antithrombotic Trialists Collaboration meta-analysis and other recent studies, the role of aspirin in primary prevention of CVD is of uncertain net value.1 Similarly, the benefit of aspirin therapy for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.